The biopharma, CRO, and border life science sectors are 'under the cosh' - not only from patent expiries and drug pricing, but also from president Trump’s recent import tariffs, Medicare price demands, and research/FDA budgetary cuts.
However, one company successfully swimming against the tide is AI-powered medical imaging expert IXICO (IXI) .
Indeed, hot on the heels of upgrading its Sept FY25 sales guidance to £6.3m (or +9% YoY), the company has today announced two new Phase 1 clinical trial contracts to provide neuroimaging analysis across Alzheimer's Disease and Friedreich's Ataxia - together adding a further £1.3m to the orderbook (£13.1m Mar'25) that will be recognised over the next 6 years.
The importance of these early-stage trials should not be underestimated either. You see, if these novel treatments reach their clinical endpoints, then the number of patients that are tested in later studies (eg P2, P3 and perhaps post-marketing surveillance too) should jump exponentially, in turn magnifying the revenues to IXICO who would more than likely remain the biotech's main neuroimaging partner.
CEO Bram Goorden commenting: "The contract wins underline the innovative, adaptable and agile nature of the IXICO platform and our teams as irrefutable thought leaders in the neurodegenerative disease space. The two deals hit different key elements of our strategy, respectively supporting Alzheimer's as a core indication, and; maintaining our leadership position in the rare CNS disease space."
House broker Cavendish has a 24p/share price target compared to today's 12p, equivalent to 1.3x EV/revs, which appears attractive for such an IPR/tech rich and expanding healthcare business.
Follow News & Updates from IXICO: